表紙
市場調查報告書

焦點市場分析:全身動脈性高血壓

Market Spotlight: Systemic Hypertension

出版商 Datamonitor Healthcare 商品編碼 858299
出版日期 內容資訊 英文 58 Pages
商品交期: 最快1-2個工作天內
價格
焦點市場分析:全身動脈性高血壓 Market Spotlight: Systemic Hypertension
出版日期: 2020年08月14日內容資訊: 英文 58 Pages
簡介

據估計,2017年全球全身動脈性高血壓的的患病率約為17億,預計到2026年將增至19億。就性別來看,男性略多一些,2017年25歲以上的患病人數中估計有53.31%是男性。批准藥物的靶點五花八門,給藥途徑主要是口服,還有少量靜脈內,肌肉內和透皮製劑。臨床開發中的大多數藥物都處於II期,其中一種藥物處於NDA / BLA期。在區域臨床試驗方面,美國大幅度領先世界,歐盟則是德國,亞洲為韓國。

本報告提供全球全身動脈性高血壓治療藥的市場調查,彙整疾病的背景·概要,患病人數的10年預測,開發平台藥物及已上市藥概要,臨床試驗狀況,授權·資產收購等的主要交易趨勢,專利資訊,主要藥物的收益預測等資料。

概要

要點

疾病的背景

治療

  • 藥物療法

流行病學

已上市藥物

開發平台藥物

近幾年的發展·分析師的見解

今後的發展

法律規章上的發展

授權·資產取得契約

成功概率

本源專利

商機

臨床試驗環境

  • 贊助商:各狀態
  • 贊助商:不同階段
  • 近幾年的發展

文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0198844

This Market Spotlight report covers the Systemic Hypertension market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 1.7 billion prevalent cases of systemic hypertension worldwide, and forecasts that number to increase to 1.9 billion prevalent cases by 2026.

Systemic hypertension has a slight male predominance. Globally, Datamonitor Healthcare estimates that in 2017, 53.31% of cases aged 25 years and over were male.

The approved drugs in the systemic hypertension space focus on a wide variety of targets. These drugs are commonly administered via the oral route, with a few products being available in intravenous, intramuscular, and transdermal formulations.

The largest proportion of industry-sponsored drugs in active clinical development for systemic hypertension are in Phase III, with only one drug in the NDA/BLA phase.

Therapies in development for systemic hypertension focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with the remainder being intranasal, subcutaneous, and topical formulations.

The only high-impact upcoming event in the systemic hypertension space is topline Phase III trial results for firibastat. The overall likelihood of approval of a Phase I systemic hypertension asset is 5.4%, and the average probability a drug advances from Phase III is 65.2%. Drugs, on average, take 6.4 years from Phase I to approval, compared to 10.0 years in the overall cardiovascular space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for hypertension have been in the late phases of development, with 51% of trials in Phase III-IV, and 49% in Phase I-II.

The US has a substantial lead in the number of hypertension clinical trials globally. Germany leads the major European markets, while South Korea has the top spot in Asia.

Clinical trial activity in the hypertension space is dominated by completed trials. Novartis has the highest number of completed clinical trials for hypertension, with 429 trials. Novartis also leads industry sponsors with by far the highest overall number of clinical trials for hypertension.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Pharmacological therapy

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Multiple Drugs for Systemic Hypertension (June 25, 2019)
  • Symplicity Renal Denervation System for Systemic Hypertension (May 22, 2019)
  • CIN-107 for Systemic Hypertension (May 14, 2019)
  • Livongo Connected Meter for Systemic Hypertension (March 18, 2019)
  • Peregrine System Infusion Catheter for Systemic Hypertension (March 7, 2019)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • AstraZeneca Divests Mature Hypertension Drugs To Atnahs
  • Daiichi Sankyo Pays ¥9.5bn For Three Marketed Astellas Products
  • Hikma Strikes Deal To Supply 14 To Civica Rx

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of systemic hypertension, 2017-26
  • Figure 2: Overview of pipeline drugs for systemic hypertension in the US
  • Figure 3: Pipeline drugs for systemic hypertension, by company
  • Figure 4: Pipeline drugs for systemic hypertension, by drug type
  • Figure 5: Pipeline drugs for systemic hypertension, by classification
  • Figure 6: Key upcoming events in systemic hypertension
  • Figure 7: Probability of success in the systemic hypertension pipeline
  • Figure 8: Clinical trials in hypertension
  • Figure 9: Top 10 drugs for clinical trials in hypertension
  • Figure 10: Top 10 companies for clinical trials in hypertension
  • Figure 11: Trial locations in hypertension
  • Figure 12: Hypertension trials status
  • Figure 13: Hypertension trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of systemic hypertension (000s), 2017-26
  • Table 2: Prevalent cases of systemic hypertension (000s), by gender, 2017
  • Table 3: Marketed drugs for systemic hypertension
  • Table 4: Pipeline drugs for systemic hypertension in the US
  • Table 5: Multiple Drugs for Systemic Hypertension (June 25, 2019)
  • Table 6: Symplicity Renal Denervation System for Systemic Hypertension (May 22, 2019)
  • Table 7: CIN-107 for Systemic Hypertension (May 14, 2019)
  • Table 8: Livongo Connected Meter for Systemic Hypertension (March 18, 2019)
  • Table 9: Peregrine System Infusion Catheter for Systemic Hypertension (March 7, 2019)
  • Table 10: Historical global sales, by drug ($m), 2015-19
  • Table 11: Forecasted global sales, by drug ($m), 2020-24